Effect of Tadalafil in Chronic Obstructive Lung Disease Patients Suffering From Secondary Pulmonary Hypertension

Herlev Hospital

Overview

Tadalafil may lower the pulmonary artery pressure in patients with Chronic Obstructive Lung Disease and secondary pulmonary hypertension and thereby improve patients quality of life.

Twenty outpatients with Chronic Obstructive Lung Disease (COPD) and secondary pulmonary hypertension are treated in a cross-over design with Tadalafil or placebo for 4 weeks. Primary effect parameter is 6 min. walking test.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

TRIPLE

Conditions

Chronic Obstructive Lung Disease

Interventions

TadalafilDRUG

40 mg tablet

Eligibility

Sex: ALLMin age: 45 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Clinical diagnosis of Chronic obstructive lung disease Exclusion Criteria * Patients with asthma

Locations (1)

Herlev University Hospital

Herlev, Denmark

Outcomes

Primary Outcomes

Change in 6 min. walking test

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.